Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

EMORY UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1836-12-10

Employees: 10K

Market Cap: -

Website: http://www.emory.edu

Clinical Trials

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Phase 2

Suspended

Conditions: Metastatic Prostate Adenocarcinoma
Stage IV Prostate Cancer AJCC v8

Interventions: Drug: VLP-encapsulated TLR9 Agonist CMP-001,
Biological: Nivolumab

First Posted Date: 2022-07-06

Last Posted Date: 2024-08-09

Lead Sponsor: Emory University

Target Recruit Count: 10

Registration Number: NCT05445609

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Behavioral Intervention to Reduce Stress Among Black Gender Minority Women

Not Applicable

Recruiting

Conditions: Stigma, Social
Psychological Distress

Interventions: Behavioral: Adaptive Intervention Approach

First Posted Date: 2022-06-28

Last Posted Date: 2025-05-23

Lead Sponsor: Emory University

Target Recruit Count: 40

Registration Number: NCT05436106

Locations: 🇺🇸
Emory University School of Nursing, Atlanta, Georgia, United States

Improving Women's Health Through Coordinated Postpartum Planning

Not Applicable

Completed

Conditions: Maternal Death
Maternal Morbidity

Interventions: Behavioral: Enhanced Postpartum Care System

First Posted Date: 2022-06-24

Last Posted Date: 2025-06-17

Lead Sponsor: Emory University

Target Recruit Count: 320

Registration Number: NCT05430815

Locations: 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States

Keeping on Course: A Communication-Focused Psychoeducational Program

Not Applicable

Recruiting

Conditions: Mild Cognitive Impairment

Interventions: Behavioral: Couple in Control (CiC) Program

First Posted Date: 2022-06-21

Last Posted Date: 2025-05-29

Lead Sponsor: Emory University

Target Recruit Count: 48

Registration Number: NCT05423912

Locations: 🇺🇸
Emory Clinic at Executive Park, Atlanta, Georgia, United States

Upper Extremity Life Care Specialist (LCS)

Not Applicable

Recruiting

Conditions: Upper Extremity Trauma

Interventions: Behavioral: Life Care Specialist (LCS)

First Posted Date: 2022-06-16

Last Posted Date: 2025-04-17

Lead Sponsor: Emory University

Target Recruit Count: 80

Registration Number: NCT05422014

Locations: 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States

Early Diagnostic Response Model (EDRM)

Not Applicable

Recruiting

Conditions: Autism
Autism Spectrum Disorder

Interventions: Behavioral: Early Diagnostic Response Model (EDRM)

First Posted Date: 2022-06-15

Last Posted Date: 2025-05-07

Lead Sponsor: Emory University

Target Recruit Count: 300

Registration Number: NCT05419895

Locations: 🇺🇸
Emory Autism Center, Atlanta, Georgia, United States

Mental Stress Reactivity in Women With CMD

Not Applicable

Recruiting

Conditions: Post-menopause

Interventions: Other: Study Procedures

First Posted Date: 2022-06-02

Last Posted Date: 2025-01-20

Lead Sponsor: Emory University

Target Recruit Count: 150

Registration Number: NCT05401630

Locations: 🇺🇸
Emory Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸
Emory Clinic, Atlanta, Georgia, United States

and more 1 locations

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

Phase 1

Recruiting

Conditions: Relapsed Osteosarcoma
Relapsed Neuroblastoma
Refractory Osteosarcoma
Neuroblastoma
Refractory Neuroblastoma

Interventions: Combination Product: Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate

First Posted Date: 2022-06-01

Last Posted Date: 2024-07-17

Lead Sponsor: Emory University

Target Recruit Count: 24

Registration Number: NCT05400603

Locations: 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Phase 1

Recruiting

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Biological: Tocilizumab
Drug: Venetoclax

First Posted Date: 2022-05-26

Last Posted Date: 2025-01-24

Lead Sponsor: Emory University

Target Recruit Count: 72

Registration Number: NCT05391750

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer

Phase 2

Active, not recruiting

Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Oropharyngeal HPV-Positive Squamous Cell Carcinoma

Interventions: Radiation: Radiation Therapy

First Posted Date: 2022-05-24

Last Posted Date: 2025-05-29

Lead Sponsor: Emory University

Target Recruit Count: 33

Registration Number: NCT05387915

Locations: 🇺🇸
Emory University Midtown Hospital, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy